CD14 and prostate cancer: In fact, by evaluating the frequency of MDSCs in the blood of prostate cancer patients the CD14+HLA-DRlow monocytic subset result to be augmented compared with sex- and age-matched healthy donors, whereas it is decreased after ADT (39, 189).